Showing results (51-60 of 83) with videos related to

Sort By:
Pageof 9
Harefuah|March 24, 2015
[Modeling integrative oncology care program for Arab patients in north Israel: towards quality of life improvement during chemotherapy]Eran Ben-Arye, Jamal Dagash, Michael Silbermann, et al.
International Journal of Molecular Sciences|July 29, 2025
Exploring the Impact of TP53 Mutation and Wild-Type Status on the Efficacy of Immunotherapy in Non-Small Cell Lung CancerAlexander Yakobson, Ronen Brenner, Itamar Gothelf, et al.
Medicina (Kaunas, Lithuania)|January 21, 2023
The Correlation between Proliferative Immunohistochemical Markers and Papillary Thyroid Carcinoma AggressivenessMohammad Sheikh-Ahmad, Yara Shalata, Jacob Bejar, et al.
Journal of Clinical Medicine|March 25, 2022
Real-World Journey of Unresectable Stage III NSCLC Patients: Current Dilemmas for Disease Staging and TreatmentAbed Agbarya, Walid Shalata, Alfredo Addeo, et al.
Cancers|April 14, 2025
Correlation Between Body Mass Index and Immunotherapy Response in Advanced NSCLCWalid Shalata, Itamar Gothelf, Yulia Dudnik, et al.
International Journal of Cancer|September 3, 2020
Alternative nivolumab duration and scheduling in advanced nonsmall cell lung cancer: A real-world evidenceElizabeth Dudnik, Mor Moskovitz, Abed Agbarya, et al.
Life (Basel, Switzerland)|July 28, 2026
Social Network Clustering Analysis for Detection of Associated Genetic Co-Mutations in Patients with Actionable Driver Mutations in NSCLCAbed Agbarya, Haitham Nasrallah, Kamel Mhameed, et al.
Frontiers in Molecular Biosciences|May 11, 2026
Variant allele frequency as a predictor of treatment response to osimertinib in EGFR-mutated NSCLCWalid Shalata, Bilal Krayim, Asmah Miari, et al.
Current Oncology (Toronto, Ont.)|August 28, 2024
Non-Small-Cell Lung Cancer Patients Harboring ROS1 Rearrangement: Real World Testing Practices, Characteristics and Treatment Patterns (ROS1REAL Study)Urska Janzic, Natalie Maimon Rabinovich, Walid Shalata, et al.
Diseases (Basel, Switzerland)|October 24, 2023
Response Rate of the Third and Fourth Doses of the BNT162b2 Vaccine Administered to Cancer Patients Undergoing Active Anti-Neoplastic TreatmentsAbed Agbarya, Ina Sarel, Tomer Ziv-Baran, et al.
Pageof 9